SecurityHUM / Humana, Inc. (444859102)
IndustryHospital and Medical Service Plans
Common Shares Outstanding137,682,171 shares (as of 2018-03-31)
Total Insiders28
Total Directors12
Total Officers17

Stock Insider Trading (from SEC Form 4)

Humana, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

HUM / Humana, Inc. insiders include Kane Brian A, MARGULIS HEIDI S, HILZINGER KURT J, BEVERIDGE, ROY A, JONES DAVID A JR/KY, Jasser Joseph William, HUNTER CHRISTOPHER H., Christopher M Todoroff, Dunbar Webster Roy, Deshpande Samir LeClaire Brian P., Wheatley Timothy Alan, and BROUSSARD BRUCE D, BILNEY JODY L, PETERSON MARISSA T, NASH DAVID, MURRAY JAMES E, MITCHELL WILLIAM, Bierbower Elizabeth D, DAMELIO FRANK A, OBRIEN JAMES J /KY, Fleming William Kevin, McDonald William J., DeSalvo Karen B, Bisignano Frank, Huval Timothy S., KAY CHRISTOPHER E, Zipperle Cynthia H, .

Insider Roster

Insider Dir Off 10% Shares Owned
HILZINGER KURT J Director
X
McDonald William J. Director
X
Wheatley Timothy Alan Segment President, Retail
X 5,187
JONES DAVID A JR/KY Director
X 90,084
LeClaire Brian P. Chief Information Officer
X 8,837
BILNEY JODY L Chief Consumer Officer
X 11,140
HUNTER CHRISTOPHER H. Chief Strategy Officer
X 12,972
Zipperle Cynthia H SVP, Chief Accounting Officer
X 5,772
Bierbower Elizabeth D Segment President, Group Bus.
X 17,381
Fleming William Kevin Seg President, Healthcare Svcs
X 8,139
BEVERIDGE, ROY A Chief Medical Officer
X 13,983
MARGULIS HEIDI S Chief Corp. Affairs Officer
X 7,776
BROUSSARD BRUCE D President & CEO, Director
X X 89,085
Huval Timothy S. Chief HR Officer
X 8,831
Kane Brian A Chief Financial Officer
X 18,459
Christopher M Todoroff Chief Legal Officer
X 9,423
Deshpande Samir Chief Risk Officer
X
Bisignano Frank Director
X 658
OBRIEN JAMES J /KY Director
X
PETERSON MARISSA T Director
X 1,434
DAMELIO FRANK A Director
X
NASH DAVID Director
X
DeSalvo Karen B Director
X
Dunbar Webster Roy Director
X 1,839
MITCHELL WILLIAM Director
X
Jasser Joseph William Seg. President, Care Delivery
X 222
KAY CHRISTOPHER E SVP & Chief Innovation Officer
X
MURRAY JAMES E EVP & COO
X 37,637

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-06-19 4 Wheatley Timothy Alan S D 299.3959 -11,468 5,187 1,552,967
2018-06-19 4 Wheatley Timothy Alan M D 217.415 3,873 16,655
2018-06-19 4 Wheatley Timothy Alan M D 164.645 8,136 12,782
2018-06-19 4 Wheatley Timothy Alan M D 217.415 459 4,646
2018-06-15 4 BILNEY JODY L S D 306.4621 -27,461 11,140 3,413,988
2018-06-15 4 BILNEY JODY L M D 164.645 20,407 38,601
2018-06-15 4 BILNEY JODY L M D 102.155 7,054 18,194
2018-06-15 4 BILNEY JODY L F D 305.765 -327 11,140
2018-06-15 4 BILNEY JODY L M D 164.645 607 11,467
2018-06-15 4 LeClaire Brian P. S D 306.1465 -5,165 8,837 2,705,417
2018-06-15 4 LeClaire Brian P. M D 217.415 5,165 14,002
2018-06-14 4 JONES DAVID A JR/KY G I -10,000 90,084
2018-06-13 4 HUNTER CHRISTOPHER H. S D 305.9883 -24,182 12,972 3,969,280
2018-06-13 4 HUNTER CHRISTOPHER H. M D 164.645 14,306 37,154
2018-06-13 4 HUNTER CHRISTOPHER H. M D 102.155 8,241 22,848
2018-06-13 4 HUNTER CHRISTOPHER H. F D 302.69 -331 14,607
2018-06-13 4 HUNTER CHRISTOPHER H. M D 164.645 607 14,938
2018-06-13 4 HUNTER CHRISTOPHER H. F D 302.69 -991 14,331
2018-06-13 4 HUNTER CHRISTOPHER H. M D 102.155 2,934 15,322
2018-06-13 4 Zipperle Cynthia H S D 306.005 -1,000 5,772 1,766,261
2018-06-11 4 Bierbower Elizabeth D S D 300.9129 -6,036 17,381 5,230,167
2018-06-11 4 Bierbower Elizabeth D M D 72.84 1,372 23,417
2018-06-11 4 Bierbower Elizabeth D M D 72.84 362 22,045
2018-06-11 4 Bierbower Elizabeth D M D 79.655 1,804 21,683
2018-06-04 4 Fleming William Kevin S D 293.0795 -15,637 8,139 2,385,374
2018-06-04 4 Fleming William Kevin M D 167.805 8,010 23,776
2018-06-04 4 Fleming William Kevin M D 164.645 7,627 15,766
2018-05-18 4 BEVERIDGE, ROY A G D -104 13,983
2018-05-03 4 BROUSSARD BRUCE D S D 286.1676 -17,604 89,085 25,493,241
2018-05-03 4 BROUSSARD BRUCE D F D 284.775 -7,469 106,689
2018-05-03 4 BROUSSARD BRUCE D F D 287.14 -22,878 114,158
2018-05-03 4 BROUSSARD BRUCE D M D 167.805 39,147 137,036
2018-05-03 4 BROUSSARD BRUCE D F D 284.775 -7,630 97,889
2018-05-03 4 BROUSSARD BRUCE D F D 287.14 -22,326 105,519
2018-05-03 4 BROUSSARD BRUCE D M D 164.645 38,935 127,845
2018-05-03 4 BROUSSARD BRUCE D F D 287.14 -349 88,910
2018-05-03 4 BROUSSARD BRUCE D M D 164.645 607 89,259
2018-05-03 4 MARGULIS HEIDI S S D 285.9021 -20,621 7,776 2,223,175
2018-05-03 4 MARGULIS HEIDI S M D 167.805 9,842 28,397
2018-05-03 4 MARGULIS HEIDI S M D 164.645 9,335 18,555
2018-05-03 4 MARGULIS HEIDI S M D 102.155 1,444 9,220
2018-03-27 4 HUNTER CHRISTOPHER H. G D -115 12,388
2018-03-09 4 Zipperle Cynthia H S D 273.3272 -1,196 7,464 2,040,114
2018-03-09 4 Zipperle Cynthia H M D 67.4825 1,196 8,660
2018-02-28 4 MARGULIS HEIDI S G D -119 7,776
2018-02-28 4 MARGULIS HEIDI S S D 275.1742 -3,727 7,895 2,172,500
2018-02-28 4 MARGULIS HEIDI S F D 276.43 -362 11,622
2018-02-28 4 MARGULIS HEIDI S M D 164.645 607 11,984
2018-02-28 4 Fleming William Kevin G D -120 8,139
2018-02-28 4 Fleming William Kevin S D 275.3496 -1,073 8,259 2,274,112
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

United Health Stock Remains a Safe, If Long Term Insurance Bet

18h investorplace
By all rational measures, United Health (NYSE:UNH) produced a very solid performance for its second quarter fiscal 2018 earnings report. The country’s biggest health-insurance provider exceeded profitability expectations, while meeting the consensus target for revenues. Still, after the financial disclosure, United Health stock dropped 2.6% before clawing its way back up on Wednesday. (41-0)

Why Dip in UnitedHealth Stock Post Q2 is a Good Entry Point

2018-07-18 zacks
UnitedHealth Group Inc. (UNH - Free Report) maintained its trend of surpassing estimates once again, with second-quarter earnings beating by 3.63%. (19-0)

How Will Membership Affect UnitedHealth's (UNH) Q2 Earnings?

2018-07-16 zacks
UnitedHealth Group Inc.’s (UNH - Free Report) second-quarter earnings should be partially offset by a decline in enrollment or the number of customers served in the second quarter. Going by the Zacks Consensus Estimate, total medical membership should be 48.89 billion members, down 1.2% year over year. (8-0)

Humana (HUM) Jointly Buys Curo, Boosts Medicare Business

2018-07-12 zacks
Humana Inc. (HUM - Free Report) recently announced that it has completed the joint acquisition of Curo Health Services (Curo) with Welsh, Carson, Anderson & Stowe (“WCAS”), collectively known as the Consortium. The transaction was approximately valued at $1.4 billion. Humana will own a 40% minority interest in this deal. A nationwide leading hospice operator, Curo caters to patients at 245 locations across 22 states. (1-0)

5 Stocks With Domestic Focus to Evade Trade War Fears

2018-07-11 zacks
On Jul 10, President Donald Trump escalated fears of a trade war further by threatening to impose 10% tariffs on an additional $200 billion of Chinese goods. The move comes within days of the two countries imposing tit-for-tat tariffs on goods worth $34 billion. This once again made investors jittery, leading to huge selloffs on Tuesday. (2-0)